Yaacov Michlin - IATI Co-Chair (Life Science)
CEO & President, Biolight.
Yaacov Michlin serves as the CEO of Biolight, an emerging global ophthalmic company focused on the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions, including glaucoma, dry eye syndrome (DES), and age-related macular degeneration (AMD).
Until 2020, Michlin was the CEO & President of Brainsway (TASE listed: BRIN), a global leader in non-invasive treatment of brain disorders. Brainsway's flagship technology is Deep TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment.
Between 2009 -2017 Michlin served as President and CEO of Yissum – the technology transfer company of the Hebrew University of Jerusalem, as well as chairman of few biotech companies including Integra - Yissum's holding company that Michlin founded that acts as a Venture Capital Fund investing in projects of the Hebrew University. He has also served for few years as Co-Chairman of the Israeli Tech Transfer Organization.
Mr. Michlin holds a Bachelor of Law and Economics, cum laude, and a Master of Law degree, both from Bar-Ilan University, Israel, and an MBA, cum laude, from the Technion Israel Institute of technology.